Hello, everyone, and how are you today? Another busy morning is unfolding here on the Pharmalot corporate campus where, once again, we are hustling short people to their school houses and urging the mascots to fertilize the weeds as quickly as possible. These challenges require a strong cup of stimulation - we are back to Pumpkin Spice this week - and invite you to quaffe something along with us. Meanwhile, here is the daily roundup of tidbits. Hope you conquer the world and do stay in touch...
Lilly Settles With Sisters Over DES Lawsuit (Associated Press)
Glaxo Says No Plan To Spin Off ViiV For Now (Bloomberg News)
Swiss Insurer Joins Yaz Lawsuit Against Bayer (Reuters)
EMA Raises Fees For Drugmakers (InPharma Technologist)
FDA Approves Bayer's Long-Term Contraceptive (Pharma Times)
ViroPharma Suit Against FDA Over Generic Vancocin Is Tossed (Bloomberg News)
Canada Releases Tamiflu Stockpile To Ease Shortage (CBC News)
UK's Hikma Buys Egypt's EPCI (Ahram Online)
EDITOR'S NOTE: Please check this post for updates
1 Comment
The list of damage to health, and death, is a long one for Lilly - topped off by its recent awful blockbuster, Zyprexa. Despite reams of internal documents showing they knew it caused massive weight gain and diabetes, and also showing how people at the highest eschelons of the company plotted off-label marketing schemes, not one person from the company has ever been indicted. Thousands of people got diabetes from this drug, and thousands died.
When will the federal government develop a backbone? This isn't just money lost - as in Wall Street crime - this is human lives.